Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E

被引:30
作者
Ostapchuk, P [1 ]
Hearing, P [1 ]
机构
[1] SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA
关键词
D O I
10.1128/JVI.75.1.45-51.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Adenoviruses (Ad) show promise as a vector system for gene delivery in vivo. However, a major challenge in the development of Ad vectors is the circumvention of the host immune responses to Ad infection, including both the host cytotoxic T-cell response and the humoral response resulting in neutralizing antibodies. One method to circumvent the effect of neutralizing antibodies against an Ad vector is to use different Ad serotypes to deliver the transgene of interest. This approach has been demonstrated with Ad genomes of highly related members of subgroup C, However, it is not known whether an Ad5-based vector DNA molecule can be packaged into capsids of evolutionarily more divergent adenoviruses, The aim of these studies was to determine if capsids containing hexon proteins from other Ad subgroups could package the Ad5 genome. A genetic approach utilizing an Ad5 temperature-sensitive (ts) mutant with a mutation in the hexon protein was used. When groan at the nonpermissive temperature, Ad5 ts147 replicates normally, providing a source of Ad5 DNA for virus assembly, but does not produce virus particles due to the hexon protein mutation, Coinfection of Ad5 ts147 with a wild-type virus of other Ad serotypes (Ad3, Ad4, or Ad9), which supply functional hexon proteins, resulted in the pseudopackaging of the Ad5 DNA genome. Furthermore, the pseudopackaged Ad5 DNA virions obtained in the coinfections were infectious. Therefore, switching herons did not impair the infectivity or uncoating process of the pseudopackaged virion. Since hexon protein is a major antigenic determinant of the Ad capsid, this approach may prove useful to reduce the antigenicity of therapeutic Ad vectors and allow repeated vector administration.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 48 条
[1]   PHYLOGENETIC-RELATIONSHIPS AMONG ADENOVIRUS SEROTYPES [J].
BAILEY, A ;
MAUTNER, V .
VIROLOGY, 1994, 205 (02) :438-452
[2]   Poly(lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo [J].
Beer, SJ ;
Matthews, CB ;
Stein, CS ;
Ross, BD ;
Hilfinger, JM ;
Davidson, BL .
GENE THERAPY, 1998, 5 (06) :740-746
[3]   Adenovirus vectors for gene delivery [J].
Benihoud, K ;
Yeh, P ;
Perricaudet, M .
CURRENT OPINION IN BIOTECHNOLOGY, 1999, 10 (05) :440-447
[4]   Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide [J].
Bouvet, M ;
Fang, B ;
Ekmekcioglu, S ;
Ji, L ;
Bucana, CD ;
Hamada, K ;
Grimm, EA ;
Roth, JA .
GENE THERAPY, 1998, 5 (02) :189-195
[5]   Gene transfer by adenovectors [J].
Brenner, M .
BLOOD, 1999, 94 (12) :3965-3967
[6]   Interactions between the immune system and gene therapy vectors: Bidirectional regulation of response and expression [J].
Bromberg, JS ;
Debruyne, LA ;
Qin, LH .
ADVANCES IN IMMUNOLOGY, VOL 69, 1998, 69 :353-409
[7]   ASSEMBLY OF ADENOVIRUS MAJOR CAPSID PROTEIN IS MEDIATED BY A NONVIRION PROTEIN [J].
CEPKO, CL ;
SHARP, PA .
CELL, 1982, 31 (02) :407-415
[8]  
Chirmule N, 1999, J IMMUNOL, V163, P448
[9]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[10]   Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response [J].
Christ, M ;
Lusky, M ;
Stoeckel, F ;
Dreyer, D ;
Dieterle, A ;
Michou, AI ;
Pavirani, A ;
Mehtali, M .
IMMUNOLOGY LETTERS, 1997, 57 (1-3) :19-25